Cargando…

Pretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta‐analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) have revolutionized the clinical treatment of multiple cancers. Recent studies revealed the potential prognostic value of the neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) in patients receiving ICIs; however, the results w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Qiaoyun, Liu, Shuxia, Liang, Caixia, Han, Xiaohong, Shi, Yuankai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166061/ https://www.ncbi.nlm.nih.gov/pubmed/30151899 http://dx.doi.org/10.1111/1759-7714.12815

Ejemplares similares

Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors
por: Zhang, Lei, et al.
Publicado: (2020)

Hematologic Complications of Immune Checkpoint Inhibitors
por: Davis, Elizabeth J., et al.
Publicado: (2019)

Hematologic complications of immune checkpoint inhibitors
por: Kroll, Michael H., et al.
Publicado: (2022)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Checkpoint inhibitors in hematological malignancies
por: Ok, Chi Young, et al.
Publicado: (2017)

Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors
por: Rogers, Barbara Barnes, et al.
Publicado: (2021)

Hematological Side Effects of Immune Checkpoint Inhibitors: The Example of Immune-Related Thrombocytopenia
por: Calvo, Roser
Publicado: (2019)

Renal Toxicities in Cancer Patients Receiving Immune-Checkpoint Inhibitors: A Meta-Analysis
por: Righini, Matteo, et al.
Publicado: (2022)

Hematological and Extra-Hematological Autoimmune Complications after Checkpoint Inhibitors
por: Fattizzo, Bruno, et al.
Publicado: (2022)

Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors
por: Panneerselvam, Kavea, et al.
Publicado: (2022)

Prognostic value of nutritional and inflammatory markers in patients with hepatocellular carcinoma who receive immune checkpoint inhibitors
por: Liu, Chunxun, et al.
Publicado: (2023)

Targeting immune checkpoints in hematological malignancies
por: Salik, Basit, et al.
Publicado: (2020)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors
por: Zhang, Liyan, et al.
Publicado: (2021)

Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors
por: Moshirfar, Majid, et al.
Publicado: (2022)

Deep learning predicts immune checkpoint inhibitor-related pneumonitis from pretreatment computed tomography images
por: Tan, Peixin, et al.
Publicado: (2022)

High‐throughput and multi‐phases identification of autoantibodies in diagnosing early‐stage breast cancer and subtypes
por: Luo, Rongrong, et al.
Publicado: (2021)

Efficacy and safety of immune checkpoint inhibitor rechallenge in non‐small cell lung cancer: A systematic review and meta‐analysis
por: Feng, Yu, et al.
Publicado: (2023)

Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC
por: Reuss, Joshua E., et al.
Publicado: (2021)

A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer
por: Tinker, Anna V., et al.
Publicado: (2023)

Prognostic value of pretreatment smoking status for small cell lung cancer: A meta‐analysis
por: Huang, Liling, et al.
Publicado: (2020)

Pretreatment hematologic markers as prognostic predictors of gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis
por: Zhou, Yu, et al.
Publicado: (2018)

Pretreatment hematologic markers as prognostic factors in patients with nasopharyngeal carcinoma: A systematic review and meta-analysis
por: Su, Li, et al.
Publicado: (2017)

Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis
por: Pantano, Francesco, et al.
Publicado: (2022)

Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC
por: Zhang, Ningning, et al.
Publicado: (2019)

Safety and Efficacy of Influenza Vaccination in Patients Receiving Immune Checkpoint Inhibitors. Systematic Review with Meta-Analysis
por: Lopez-Olivo, Maria A., et al.
Publicado: (2022)

Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors
por: Awadalla, Magid, et al.
Publicado: (2019)

QUALITY OF LIFE IN OLDER ADULTS RECEIVING IMMUNE CHECKPOINT INHIBITOR THERAPY
por: Hoogland, Aasha I, et al.
Publicado: (2019)

Risk of COVID‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors
por: Klebanov, Nikolai, et al.
Publicado: (2021)

Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors
por: Vasavada, Shaleen, et al.
Publicado: (2022)

Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors
por: Torrente, María, et al.
Publicado: (2022)

Incidence and Risk of Hematological Adverse Events Associated With Immune Checkpoint Inhibitors: A Systematic Literature Review and Meta-Analysis
por: Ohashi, Takuma, et al.
Publicado: (2023)

Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
por: Zhuang, Junling, et al.
Publicado: (2020)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
por: Sisi, Monia, et al.
Publicado: (2023)

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
por: Valero, Cristina, et al.
Publicado: (2021)

Pretreatment nutritional status and response to checkpoint inhibitors in lung cancer
por: Lee, Chung-Shien, et al.
Publicado: (2020)

Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma
por: Sun, Tao, et al.
Publicado: (2023)

Clinical and Hematological Predictors of High-Grade Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors
por: Manne, Ashish, et al.
Publicado: (2021)

38351 Immune-related adverse events in cancer patients receiving immune checkpoint inhibitors
por: Lucas, Margaret Byrnethew, et al.
Publicado: (2021)

Prognostic role of pretreatment (18)F-FDG PET/CT and hematological parameters in relapsed/refractory Hodgkin lymphoma patients treated with immune checkpoint inhibitors and chemotherapy: a dual-center cohort study
por: Yang, Tianyu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b11bs6bfl97rlag7a51lbv62gt